Previous 10 | Next 10 |
Halozyme Therapeutics ( HALO ) announced that its product PEGPH20 failed to achieve statistical significance in a phase 3 study treating patients with metastatic pancreatic cancer. This was a major setback for the company and its shareholders. However, this move prompted it to move quickly...
Apellis Pharma (NASDAQ: APLS ) initiated with Neutral rating and $33 (8% upside) price target at Credit Suisse. More news on: Apellis Pharmaceuticals, Inc., Aphria Inc., argenx SE, Healthcare stocks news, Stocks on the move, , Consumer stocks news, Read more ...
Citing its intent to focus its resources on it ENHANZE drug delivery technology, Halozyme Therapeutics ( HALO +1.1% ) will terminate development of PEGPH20, shut down its oncology operations and cut 160 jobs representing ~55% of its workforce. Most (~80%) of the layoffs will be done by e...
SAN DIEGO , Nov. 4, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced strategic actions to reposition the Company with a focus solely on its ENHANZE ® drug delivery technology. In order to implement this strategic shift, Halozyme will immediately ...
SAN DIEGO , Nov. 4, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the HALO-301 Phase 3 clinical study evaluating investigational new drug PEGPH20 as a first-line therapy for treatment of patients with metastatic pancreas cancer failed to reach the pr...
SAN DIEGO , Oct. 21, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the third quarter 2019 on Tuesday, November 12 at 4:30 p.m. ET / ...
SAN DIEGO , Sept. 23, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the 2019 Cantor Global Healthcare Conference in New York, NY . Dr. Helen Torley , presiden...
A Phase 3 clinical trial, FeDeriCa , evaluating the subcutaneous (SC) administration of a fixed-dose combination of Roche's ( OTCQX:RHHBY ) Herceptin (trastuzumab) and Perjeta (pertuzumab) plus chemo in patients with HER2-positive early-stage breast cancer showed it to be non-inferior to ...
Halozyme Therapeutics (NASDAQ: HALO ) announces that the global phase III FeDeriCa study conducted by Genentech, met its primary endpoint. The study investigated a fixed-dose combination of pertuzumab (Perjeta) and trastuzumab (Herceptin) for subcutaneous administration using Halozyme's EN...
SAN DIEGO , Sept. 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, met its ...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...